Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Plus Therapeutics Inc PSTV

Healthcare Biotechnology
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers. The Company combines image-guided local beta radiation and targeted drug delivery approaches. The Company is advancing a pipeline of product candidates with lead programs in recurrent glioblastoma... see more

Recent & Breaking News (NDAQ:PSTV)

Cytori Presents Scleroderma Clinical Trial Data at the 2016 American College of Rheumatology Annual Meeting

Business Wire October 26, 2016

Cytori Publication on Cytori Cell Therapy for Combined Radiation and Thermal Injury

Business Wire October 24, 2016

Cytori Partner Kerastem Completes Enrollment of US Phase II Trial for Early Stage Hair Loss

Business Wire September 26, 2016

BARDA Increases Contract Option with Cytori to Advance Countermeasure Clinical Trial

Business Wire September 19, 2016

Cytori to Present in Investor Events in September 2016

Business Wire September 1, 2016

Cytori Therapeutics Receives Frost & Sullivan 2016 Technology Innovation Award

Business Wire August 22, 2016

Cytori Therapeutics Announced Inducement Grant for New Employee

Business Wire August 5, 2016

Cytori Reports Second Quarter 2016 Business and Financial Results

Business Wire August 4, 2016

Cytori to Webcast Second Quarter Financial Results on August 4

Business Wire July 22, 2016

Cytori Cell Therapy™ Phase I Trial Reports Maxillofacial Bone Regeneration

Business Wire July 19, 2016

Cytori ATHENA Trial for Chronic Ischemic Cardiovascular Disease

Business Wire June 28, 2016

Cytori Cell Therapy Receives Limited Approval for Osteoarthritis in Japan

Business Wire June 27, 2016

Cytori Closes Rights Offering for Gross Proceeds of $17.1 Million

Business Wire June 15, 2016

10 Stocks Moving In Monday's Pre-Market Session

Benzinga.com  June 13, 2016

Cytori Announces Expiration of Rights Offering and Estimated Gross Proceeds of $17.1 Million

Business Wire June 13, 2016

Cytori Cell Therapy™ Leads to Improved Function and Reduced Scar Tissue in a Urinary Injury Model

Business Wire June 10, 2016

Presentation of Twelve Month Pilot Trial Data of Cytori® Cell Therapy™ for ACL Reconstruction

Business Wire June 8, 2016

Cytori Announces Enrollment Completion in U.S. Phase III Scleroderma Trial

Business Wire June 7, 2016

Cytori Extends Rights Offering Subscription Period to Friday, June 10, and Adjusts Unit Pricing

Business Wire June 6, 2016

Cytori Announces Commencement of Subscription Period for Previously Announced Rights Offering

Business Wire May 31, 2016